Fucosylated Glycans in α1-Acid Glycoprotein for Monitoring Treatment Outcomes and Prognosis of Cancer Patients.
One standard treatment option for advanced-stage cancer is surgical resection of malignant tumors following by adjuvant chemotherapy and chemoradiotherapy. Additionally, neoadjuvant chemotherapy may be applied if required. During the time course of treatments, patients are generally followed by computed tomography (CT) surveillance, and by tumor marker diagnosis. However, currently, early evidence of recurrence and/or metastasis of tumors with a clinically relevant biomarker remains a major therapeutic challenge. In particular, there has been no validated biomarker for predicting treatment outcomes in therapeutic settings. Recently, we have looked at glycoforms of serum α1-acid glycoprotein (AGP) by using a crossed affinoimmunoelectrophoresis with two lectins and an anti-AGP antibody. The primary glycan structures of AGP were also analyzed by a mass spectrometer and a novel software in a large number of patients with various cancers. Accordingly, the relative abundance of α1,3fucosylated glycans in AGP (FUCAGP) was found to be significantly high in cancer patients as compared with the healthy controls. Further, strikingly elevated levels of FUCAGP were found in patients with poor prognosis but not in patients with good prognosis. In the current study, levels of FUCAGP in serum samples from various cancer patients were analyzed and 17 patients including 13 who had undergone chemotherapy were followed for several years post operation. FUCAGP level determined diligently by using a mass spectrometer was found to change along with disease prognosis as well as with responses to treatments, in particular, to various chemotherapies. Therefore, FUCAGP levels measured during following-up of the patients after operation appeared to be clinically relevant biomarker of treatment intervention.
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
Shin
S
Yazawa
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
Ryo
R
Takahashi
Department of Molecular and Cellular Pharmacology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Takehiko
T
Yokobori
Department of Legal Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan.
Rie
R
Sano
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
Akira
A
Mogi
Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Abby R
AR
Saniabadi
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
Hiroyuki
H
Kuwano
Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Maebashi, Japan.|Big Data Center for Integrative Analysis, Gunma University Initiative for Advance Research, Maebashi, Japan.
Takayuki
T
Asao
D014408:Biomarkers, Tumor / Q000097:blood*; D002240:Carbohydrate Sequence; D016022:Case-Control Studies; D005643:Fucose / Q000378:metabolism; D006031:Glycosylation; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D009961:Orosomucoid / Q000032:analysis*; D011134:Polysaccharides / Q000032:analysis / Q000097:blood* / Q000378:metabolism; D011184:Postoperative Period; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D009961:Orosomucoid; D011134:Polysaccharides; D005643:Fucose